VEGFA Polyclonal Antibody
Applications
Reactivity
Predicted Reactivity
Overview | |
Catalog # | bs-1313R |
Product Name | VEGFA Polyclonal Antibody |
Applications | WB, IHC-P, IF(IHC-P) |
Reactivity | Human, Mouse, Rat, Rabbit |
Predicted Reactivity | Dog, Cow, Chicken, Pig |
Specifications | |
Conjugation | Unconjugated |
Host | Rabbit |
Source | KLH conjugated synthetic peptide derived from human VEGF |
Clonality | Polyclonal |
Isotype | IgG |
Concentration | 1ug/ul |
Purification | Purified by Protein A. |
Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Storage Condition | Store at -20°C for 12 months. |
Target | |
Gene ID | 7422 |
Swiss Prot | P15692 |
Subcellular location | Secreted, Extracellular matrix |
Synonyms | Vascuoar endothelial growth factor A; VEGF A; vascular endothelial growth factor A isoform 2 precursor; MGC70609; MVCD1; VEGF; VPF; VEGFA_HUMAN; VEGF-A; Vascular permeability factor (VPF); |
Background | This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms. Function : Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. |
Application Dilution | |
WB | |
IHC-P | 1:200-400 |
IF(IHC-P) | 1:50-200 |